购物车
- 全部删除
- 您的购物车当前为空
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 178 | 现货 | |
5 mg | ¥ 455 | 现货 | |
10 mg | ¥ 637 | 现货 | |
25 mg | ¥ 1,130 | 现货 | |
50 mg | ¥ 1,860 | 现货 | |
100 mg | ¥ 2,950 | 现货 | |
200 mg | ¥ 3,970 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 492 | 现货 |
产品描述 | Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. |
体外活性 | Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF)[1]. |
体内活性 | In cancer models where MET is the dominant oncogenic driver, anticancer activity could be further enhanced by combination treatments, for example, by the addition of apoptosis-inducing BH3 mimetics.?The combinations of capmatinib and other kinase inhibitors resulted in enhanced anticancer activity against models where MET activation co-occurred with other oncogenic drivers, for example EGFR activating mutations[1]. |
别名 | NVP-INC280 2HCl.H2O, INCB28060 2HCl.H2O, INC-280 2HCl.H2O |
分子量 | 503.36 |
分子式 | C23H21Cl2FN6O2 |
CAS No. | 1865733-40-9 |
Smiles | O=C(C1=C(F)C=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1)NC.Cl.O.Cl |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 30 mg/mL (59.6 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
评论内容